Oncology

News

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

Oncology

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

News

Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.

News

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and Black women.

News

A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.